摘要
目的探讨培美曲赛联合顺铂治疗晚期非小细胞肺癌的疗效及毒副反应。方法选择70例患者，分为PEM组、GP组各35例，分别接受培美曲赛联合顺铂与吉西他滨联合顺铂治疗。PEM组给予PEM 500mg/m2，d1，DDP 75mg/m2，d1、d2、d3；GP组给与GEM 1000mg/m2，d1、d8，DDP 75mg/m2，d1、d2、d3；21d为1个周期，2个周期后评价疗效。结果 PEM组近期有效率为37.14%，GP组近期有效率为31.43%，组间差异无统计学意义(P>0.05)；血液毒性PEM组低于GP组(P<0.05)，差异有统计学意义。结论培美曲赛联合顺铂治疗晚期非小细胞肺癌近期疗效不劣于吉西他滨联合顺铂，但在不良反应方面PEM组发生率明显减低，耐受性好，值得临床应用。
Abstract
Objective To investigate efficacy and toxicities of pemetrexed in combination with cisplaton in previously treated patients with NSCLC. Methods Select 70 patients, divided into PEM group(35 cases), GP group(35 cases), PEM group: received treaty of pemetrexed 500mg/m2, d1, >10min ivgtt, DDP 75mg/m2 d1, d2, d3; GP group: GEM 1000mg/m2, d1, d8, DDP 75mg/m2, d1, 12, d3. To evaluate efficacy after 2 cycles. Results PEM group: RR were 37.14%. GP group: RR were 31.43%. The main toxicities was the blood toxicity. Conclusion Pemetrexed combined with cisplaton is an ideal option for advanced NSCLC. But in terms of adverse reactions to significantly reduce the incidence of PEM group, tolerance is good, is worth further clinical application.
NETL
NSTL
维普
万方数据